• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer.

作者信息

Arbyn Marc, Rousta Pegah, Bruni Laia, Schollin Ask Lina, Basu Partha

机构信息

Unit of Cancer Epidemiology, Belgian Cancer Centre, Scientific Institute of Public Health, Brussels, Belgium.

Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, University Ghent, Ghent, Belgium.

出版信息

J Natl Cancer Inst. 2024 Jun 7;116(6):775-778. doi: 10.1093/jnci/djae042.

DOI:10.1093/jnci/djae042
PMID:38501990
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11160490/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed04/11160490/1c2c3f769848/djae042f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed04/11160490/1c2c3f769848/djae042f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed04/11160490/1c2c3f769848/djae042f1.jpg

相似文献

1
Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer.个体患者数据的关联证实了预防性人乳头瘤病毒疫苗对浸润性宫颈癌的保护作用。
J Natl Cancer Inst. 2024 Jun 7;116(6):775-778. doi: 10.1093/jnci/djae042.
2
Human Papillomavirus Vaccination.人乳头瘤病毒疫苗接种。
N Engl J Med. 2023 May 11;388(19):1790-1798. doi: 10.1056/NEJMcp2108502.
3
[Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].[人乳头瘤病毒疫苗接种前景及子宫颈肿瘤筛查的影响]
Bull Mem Acad R Med Belg. 2007;162(10-12):483-8; discussion 489-90.
4
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.接种人乳头瘤病毒预防性疫苗以预防宫颈癌及其癌前病变。
Cochrane Database Syst Rev. 2018 May 9;5(5):CD009069. doi: 10.1002/14651858.CD009069.pub3.
5
Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation.二价人乳头瘤病毒疫苗接种后浸润性宫颈癌的发病率：基于人群的免疫年龄、剂量和贫困程度观察性研究。
J Natl Cancer Inst. 2024 Jun 7;116(6):857-865. doi: 10.1093/jnci/djad263.
6
HPV vaccinations: a Middle Eastern and north African dilemma.人乳头瘤病毒疫苗接种：中东和北非地区的困境
Lancet Infect Dis. 2017 Jan;17(1):18-19. doi: 10.1016/S1473-3099(16)30553-9.
7
A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.一种四价预防性疫苗，用于预防 HPV-6、-11、-16 和 -18 型感染及相关疾病。
Expert Rev Vaccines. 2012 Apr;11(4):395-406. doi: 10.1586/erv.12.20.
8
Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination.14年HPV疫苗接种期间基于人群的宫颈上皮内瘤变发病率
JAMA Oncol. 2024 Sep 1;10(9):1287-1290. doi: 10.1001/jamaoncol.2024.2673.
9
Prophylactic human papillomavirus vaccination: a breakthrough in primary cervical cancer prevention.预防性人乳头瘤病毒疫苗接种：原发性宫颈癌预防的一项突破。
Obstet Gynecol Clin North Am. 2007 Dec;34(4):761-81, ix. doi: 10.1016/j.ogc.2007.09.007.
10
Extending vaccination periods against human papillomavirus: Lessons from the SARS-CoV-2 pandemic.延长人乳头瘤病毒疫苗接种周期：来自新冠疫情的经验教训
BJOG. 2024 Jun;131(7):877-879. doi: 10.1111/1471-0528.17748. Epub 2024 Jan 15.

引用本文的文献

1
Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study.四价人乳头瘤病毒疫苗按年龄和剂次对高级别宫颈病变的有效性：一项基于人群的队列研究
Lancet Reg Health Eur. 2025 Jan 5;49:101178. doi: 10.1016/j.lanepe.2024.101178. eCollection 2025 Feb.
2
Impact of a national HPV vaccination programme for preadolescent girls on cytology screening performance and CIN2+ incidence: five-year population-based cervical screening results from Slovenia.一项针对青春期前女孩的全国性人乳头瘤病毒（HPV）疫苗接种计划对细胞学筛查效果和CIN2+发病率的影响：来自斯洛文尼亚的基于人群的五年宫颈筛查结果
Lancet Reg Health Eur. 2024 Dec 28;50:101203. doi: 10.1016/j.lanepe.2024.101203. eCollection 2025 Mar.
3

本文引用的文献

1
Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation.二价人乳头瘤病毒疫苗接种后浸润性宫颈癌的发病率：基于人群的免疫年龄、剂量和贫困程度观察性研究。
J Natl Cancer Inst. 2024 Jun 7;116(6):857-865. doi: 10.1093/jnci/djad263.
2
Cervical cancer screening improvements with self-sampling during the COVID-19 pandemic.新冠肺炎大流行期间自我采样对宫颈癌筛查的改善。
Elife. 2023 Dec 12;12:e80905. doi: 10.7554/eLife.80905.
3
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccine.
Prophylactic HPV vaccination in HPV-related gynecologic cancers: European Society of Gynecological Oncology (ESGO) prevention committee opinion.人乳头瘤病毒（HPV）相关妇科癌症的预防性HPV疫苗接种：欧洲妇科肿瘤学会（ESGO）预防委员会意见
Int J Gynaecol Obstet. 2025 May;169(2):597-604. doi: 10.1002/ijgo.16120. Epub 2024 Dec 30.
4
Acceptability of single-dose HPV vaccination schedule among health-care professionals in Kenya: a mixed-methods study.肯尼亚卫生保健专业人员对单剂 HPV 疫苗接种方案的可接受性：一项混合方法研究。
J Natl Cancer Inst Monogr. 2024 Nov 1;2024(67):358-370. doi: 10.1093/jncimonographs/lgae031.
5
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccination.一项前瞻性队列研究比较了接种一剂四价人乳头瘤病毒疫苗与接种两剂和三剂疫苗在接种后 12 年的平均随访时间内的疗效。
J Natl Cancer Inst Monogr. 2024 Nov 1;2024(67):317-328. doi: 10.1093/jncimonographs/lgae042.
接种年龄和宫颈 HPV 感染状况对接受单剂或更高剂量四价 HPV 疫苗 10 年后结合抗体和中和抗体效价的影响。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2289242. doi: 10.1080/21645515.2023.2289242. Epub 2023 Dec 11.
4
The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.英国英格兰国家 HPV 疫苗接种计划对宫颈癌和 3 级宫颈上皮内瘤变发病率的影响：基于登记的观察性研究。
Lancet. 2021 Dec 4;398(10316):2084-2092. doi: 10.1016/S0140-6736(21)02178-4. Epub 2021 Nov 3.
5
Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer.人乳头瘤病毒疫苗接种预防宫颈癌的真实世界效果。
J Natl Cancer Inst. 2021 Oct 1;113(10):1329-1335. doi: 10.1093/jnci/djab080.
6
Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.美国 30 至 45 岁成人接种人乳头瘤病毒疫苗的成本效益分析。
PLoS Med. 2021 Mar 11;18(3):e1003534. doi: 10.1371/journal.pmed.1003534. eCollection 2021 Mar.
7
HPV Vaccination and the Risk of Invasive Cervical Cancer.HPV 疫苗接种与浸润性宫颈癌风险。
N Engl J Med. 2020 Oct 1;383(14):1340-1348. doi: 10.1056/NEJMoa1917338.
8
The European response to the WHO call to eliminate cervical cancer as a public health problem.欧洲对世界卫生组织消除宫颈癌这一公共卫生问题的呼吁的回应。
Int J Cancer. 2021 Jan 15;148(2):277-284. doi: 10.1002/ijc.33189. Epub 2020 Aug 4.
9
Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices.人乳头瘤病毒疫苗接种：免疫实践咨询委员会的最新建议。
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702. doi: 10.15585/mmwr.mm6832a3.
10
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.人群水平影响和 herd 效应：人乳头瘤病毒疫苗接种计划引入后的更新系统评价和荟萃分析。
Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26.